A Study Following People With Haemophilia A and B, With or Without Inhibitors, When on Usual Treatment (Explorer™6)
Public ClinicalTrials.gov record NCT03741881. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Prospective, Multi-national, Non-interventional Study in Haemophilia A and B Patients With or Without Inhibitors Treated According to Routine Clinical Treatment Practice (Explorer™6)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will collect data on bleeds and data related to quality of life in people with severe congenital (a disease existing from birth) haemophilia A and B, with or without inhibitors. The aim for the study is to look at the number of bleeds when on usual treatment for haemophilia. Participants will be asked to keep an electronic diary to track the number of bleeds and the treatment of their bleeds. Participants will be asked to wear an activity tracker on their wrist to capture their level of activity every day for up to 12 weeks. While taking part in this study, participants will keep getting their usual treatment as given to them by their doctor. All study visits at the clinic are done in the same way as the participants are used to. In the time between the participants' visits to the clinic, the study staff at the clinic may call or email the participant. The study will last for about 2½ years.
Study identification
- NCT ID
- NCT03741881
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 231 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 18, 2018 (Actual)
- Primary completion
- Oct 25, 2021 (Actual)
- Completion
- Oct 25, 2021 (Actual)
- Last update posted
- Nov 23, 2021
2018 – 2021
United States locations
- U.S. sites
- 29
- U.S. states
- 20
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novo Nordisk Investigational Site | Los Angeles | California | 90027 | — |
| Novo Nordisk Investigational Site | Sacramento | California | 95817 | — |
| Novo Nordisk Investigational Site | Aurora | Colorado | 80045 | — |
| Novo Nordisk Investigational Site | Washington D.C. | District of Columbia | 20007 | — |
| Novo Nordisk Investigational Site | Atlanta | Georgia | 30322 | — |
| Novo Nordisk Investigational Site | Augusta | Georgia | 30912 | — |
| Novo Nordisk Investigational Site | Macon | Georgia | 31201 | — |
| Novo Nordisk Investigational Site | Chicago | Illinois | 60612 | — |
| Novo Nordisk Investigational Site | Indianapolis | Indiana | 46260 | — |
| Novo Nordisk Investigational Site | Detroit | Michigan | 48201 | — |
| Novo Nordisk Investigational Site | East Lansing | Michigan | 48823 | — |
| Novo Nordisk Investigational Site | St Louis | Missouri | 63110 | — |
| Novo Nordisk Investigational Site | Las Vegas | Nevada | 89135 | — |
| Novo Nordisk Investigational Site | Newark | New Jersey | 07102 | — |
| Novo Nordisk Investigational Site | Albuquerque | New Mexico | 87131 | — |
| Novo Nordisk Investigational Site | Charlotte | North Carolina | 28203 | — |
| Novo Nordisk Investigational Site | Charlotte | North Carolina | 28204 | — |
| Novo Nordisk Investigational Site | Cleveland | Ohio | 44106 | — |
| Novo Nordisk Investigational Site | Dayton | Ohio | 45404 | — |
| Novo Nordisk Investigational Site | Hershey | Pennsylvania | 17033 | — |
| Novo Nordisk Investigational Site | Philadelphia | Pennsylvania | 19104 | — |
| Novo Nordisk Investigational Site | Philadelphia | Pennsylvania | 19134 | — |
| Novo Nordisk Investigational Site | Charleston | South Carolina | 29425 | — |
| Novo Nordisk Investigational Site | Nashville | Tennessee | 37232-9830 | — |
| Novo Nordisk Investigational Site | Houston | Texas | 77030 | — |
| Novo Nordisk Investigational Site | San Antonio | Texas | 78229 | — |
| Novo Nordisk Investigational Site | Salt Lake City | Utah | 84113 | — |
| Novo Nordisk Investigational Site | Charlottesville | Virginia | 22908 | — |
| Novo Nordisk Investigational Site | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 114 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03741881, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 23, 2021 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03741881 live on ClinicalTrials.gov.